论文部分内容阅读
目的:探讨达力通颗粒联合泮托拉唑治疗老年反流性食管炎患者的临床疗效性和安全性。方法:选择2012年5月—2013年4月我院收治的76例老年反流性食管炎患者作为观察对象,随机分为观察组和对照组,每组各38例。对照组给予泮托拉唑钠肠溶片口服,观察组在对照组基础上给予中成药达力通颗粒治疗,疗程4周。观察治疗后两组患者症状疗效和内镜下食管改善情况,并对不良反应发生情况进行分析。结果:在临床症状方面,治疗后,两组临床症状积分无明显差异(P>0.05),而观察组总有效率为92.1%,明显低于对照组68.4%,差异具有显著性(P>0.05);观察组疗程结束后内镜下改善情况明显优于对照组,差异具有显著性(P>0.05);两组患者不良反应均较轻微,无明显差异。结论:达力通颗粒联合泮托拉唑治疗老年反流性食管炎患者,能够有效改善临床症状和内镜下食管情况,疗效确切,安全性较稳定,值得临床推广应用。
Objective: To investigate the clinical curative effect and safety of dalitone particles combined with pantoprazole in the treatment of elderly patients with reflux esophagitis. Methods: Seventy-six elderly patients with reflux esophagitis admitted to our hospital from May 2012 to April 2013 were randomly divided into observation group and control group, with 38 cases in each group. The control group was given pantoprazole sodium enteric-coated tablets orally, and the observation group was treated with the Chinese patent medicine Dalitong Granule on the basis of the control group for 4 weeks. After treatment, the symptoms and signs of esophagus and endoscopic esophageal mucosa in both groups were observed, and the incidence of adverse reactions was analyzed. Results: There was no significant difference in clinical symptom scores between the two groups (P> 0.05), but the total effective rate was 92.1% in the observation group, which was significantly lower than that in the control group (68.4%), the difference was significant (P> 0.05 ); Endoscopic treatment group after the end of treatment improved significantly better than the control group, the difference was significant (P> 0.05); two groups of patients with mild adverse reactions, no significant difference. Conclusion: The treatment of elderly patients with reflux esophagitis by dalateng granules combined with pantoprazole can effectively improve clinical symptoms and endoscopic esophageal conditions. The curative effect is definite and the safety is relatively stable, which is worthy of clinical application.